Literature DB >> 26885092

Prophylaxis on gout flares after the initiation of urate-lowering therapy: a retrospective research.

Xin Feng1, Yao Li2, Wei Gao1.   

Abstract

The objective of this study was to evaluate the efficacy and safety associated with treatment available to prevent an acute attack of gout when initiating a urate-lowering therapy (ULT). We retrospectively reviewed patients who were diagnosed with gout and treated with ULT during the period from January 2000 to January 2014. They were divided into three groups, 75 patients without prophylaxis treatment, 103 patients treated with etoricoxib, and 129 patients with colchicine treatment. Both demographic and clinical characteristics associated with gout were analyzed. At baseline, demographic and clinical characteristics were generally similar in three groups. SU target level was achieved in 49.3% of the patients without prophylaxis treatment, 66.4% in the etoricoxib group and 65.1% in colchicine group, respectively. During the first 16 weeks, patients without prophylaxis treatment exhibited higher flare rates than patients in other two groups. However, no statistically significant difference was observed between patients in etoricoxib group and colchicine group. In the 16-24 weeks, the proportion of patients who reported flares were all decreased similarly in three groups. The mean number of acute gout flares per patient and gout flare days per patient was significantly higher in patients without prophylaxis treatment than patients in other groups. The mean number of acute gout flares was lower (4.2±2.3 vs 3.2±1.8) in patients with etoricoxib treatment than that in patients with colchicine treatment. Gout flare days per patient were significantly higher in patients without prophylaxis treatment. Compared to colchicine group, gout flare days per patient in etoricoxib were lower (1.2±0.5 vs 2.6±0.6). In term of AEs, patients receiving colchicine had higher rates of gastrointestinal AEs than those who received etoricoxib. In summary, our survey revealed that etoricoxib was more effective and safe than colchicine in preventing acute attack during ULT.

Entities:  

Keywords:  Gout; colchicine; etoricoxib

Year:  2015        PMID: 26885092      PMCID: PMC4723937     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  14 in total

1.  Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy.

Authors:  Michael A Becker; Patricia A MacDonald; Barbara J Hunt; Christopher Lademacher; Nancy Joseph-Ridge
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2008-06       Impact factor: 1.381

2.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

3.  2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Authors:  Dinesh Khanna; Puja P Khanna; John D Fitzgerald; Manjit K Singh; Sangmee Bae; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

4.  Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.

Authors:  Robert L Wortmann; Patricia A Macdonald; Barbara Hunt; Robert L Jackson
Journal:  Clin Ther       Date:  2010-12       Impact factor: 3.393

Review 5.  Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.

Authors:  Shaobo Zhang; Yibao Zhang; Peng Liu; Wei Zhang; Jing-Lin Ma; Jing Wang
Journal:  Clin Rheumatol       Date:  2015-06-24       Impact factor: 2.980

6.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

Authors:  Michael A Becker; H Ralph Schumacher; Luis R Espinoza; Alvin F Wells; Patricia MacDonald; Eric Lloyd; Christopher Lademacher
Journal:  Arthritis Res Ther       Date:  2010-04-06       Impact factor: 5.156

7.  Uric acid lowering therapy: prescribing patterns in a large cohort of older adults.

Authors:  D H Solomon; J Avorn; R Levin; M A Brookhart
Journal:  Ann Rheum Dis       Date:  2007-08-29       Impact factor: 19.103

8.  A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy.

Authors:  Akira Shoji; Hisashi Yamanaka; Naoyuki Kamatani
Journal:  Arthritis Rheum       Date:  2004-06-15

9.  Management of gout: a 57-year-old man with a history of podagra, hyperuricemia, and mild renal insufficiency.

Authors:  Robert H Shmerling
Journal:  JAMA       Date:  2012-11-28       Impact factor: 56.272

10.  Formulation of colchicine ointment for the treatment of acute gout.

Authors:  Sairam Maduri; Venkateshwar Reddy Atla
Journal:  Singapore Med J       Date:  2012-11       Impact factor: 1.858

View more
  2 in total

1.  Combined Use of Febuxostat and Colchicine Does Not Increase Acute Hepatotoxicity in Patients with Gout: A Retrospective Study.

Authors:  Yoon-Jeong Oh; Ki Won Moon
Journal:  J Clin Med       Date:  2020-05-15       Impact factor: 4.241

Review 2.  Physiology of Hyperuricemia and Urate-Lowering Treatments.

Authors:  Caroline L Benn; Pinky Dua; Rachel Gurrell; Peter Loudon; Andrew Pike; R Ian Storer; Ciara Vangjeli
Journal:  Front Med (Lausanne)       Date:  2018-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.